Monokine-stimulated endothelial cells are known to produce both burst-and colony-stimulating activities, but neither the nature of the monokine nor the hematopoietic growth factor(s) produced is known. We show by mRNA analysis that an immortalized line of human endothelial cells constitutively produce grknulocyte-macrophage colony-stimulating factor. Furthermore, interleukin 1 and tumor necrosis factor induce early passage human umbilical endothelial cells to produce the same growth factor.
Introduction
Pluripotent stem cells and progenitors proliferate and differentiate only in the microenvironment of bone marrow, liver, or spleen, but the precise roles of the reticular, macrophage, and endothelial cells comprising this hematopoietic microenvironment are uncertain (1, 2) . We recently demonstrated that a stromal reticular fibroblastoid cell strain produces a factor (or factors) with colony-stimulating activity (CSA)' and burst-promoting activity (BPA), capable of inducing the formation of granulocyte-macrophage colony-forming units (CFU GM), erythroid burst-forming units (BFU E), and mixed granulocyte erythroid macrophage CFU (3) . Cultured human endothelial cells have also been shown to produce CSA (4, 5) and BPA (6) , whereas monocytes and/or macrophages not only produce CSA (7, 8) , BPA (9, 10) , and/or factors that inhibit colony formation (1 1) , but also secrete a monokine, "monocyte-derived recruiting activity," that increases CSA and BPA production by endothelial cells (12, 13) , fibroblasts (14) , and T lymphocytes (15). Neither the monokine nor the specific CSA/BPA produced have been identified.
In this paper we show that an immortalized line of human endothelial cells constitutively produces granulocyte-macrophage colony-stimulating factor (GM CSF), a multilineage he-1. Abbreviations used in this paper: BFU E, erythroid burst-forming unit; BPA, burst-promoting activity; CFU E, erythroid colony-forming unit; CFU GM, granulocyte-macrophage colony-forming unit; CM, conditioned medium; CSA, colony-stimulating activity; GM CSF, GM colony-stimulating factor; HEC KSV, human endothelial cells immortalized by the Kirsten sarcoma virus; HUVE, human umbilical vein endothelial cells; IL-1, interleukin 1, IFN, interferon; Mo-CM, Mo T lymphoblast cell line CM; TNF, tumor necrosis factor. matopoietin (16) . We also demonstrate that both the monokines interleukin 1 (IL-1) and tumor necrosis factor (TNF) induce early passage human umbilical vein endothelial cells (HUVE) to produce GM CSF.
Methods
Bone marrow samples. Normal human bone marrow was obtained by aspiration from adult volunteers. Approximately 5-15 ml from one to two aspirations was collected into sterile syringes containing preservativefree heparin.
Cell separation procedures. The marrow suspensions were separated over Ficoll-Paque (1.007 g/ml) (Pharmacia Fine Chemicals, Piscataway, NJ) at 400 g for 40 min at 20'C and the interface mononuclear cells collected, washed three times, and resuspended in Iscove's modified Dulbecco's medium containing 20% fetal calf serum (FCS). The cells were incubated in 100-mm tissue culture dishes (Lux, Miles Laboratories Inc., Naperville, IL) overnight at 370C and the nonadherent cells removed with two gentle washes and centrifuged. The progenitors in the nonadherent cell fraction were enriched by immunoadsorption to Ig-coated plates (panning), as previously described (17 10 ,ug/ml in PBS. After 40 min, the plates were washed three times in PBS and then incubated at 4°C in 5 ml PBS/l% FCS until required.
Cultureprocedures. The bone marrow cells were cultured in a mixture containing 30% FCS, 1% bovine serum albumin (BSA; Sigma Chemical Co., St. Louis, MO), 10'-M mercaptoethanol (Sigma Chemical Co.), penicillin/streptomycin, and 0.9% methyl cellulose. Varying concentrations ofthe conditioned media to be tested or Mo-cell lymphoblast lineconditioned medium (Mo-CM) as a positive control (provided by Drs. D. Golde and J. Gasson, University ofCalifornia at Los Angeles, School of Medicine, Los Angeles, CA) were added on day 0, and on day 3 human urinary erythropoietin (Terry Fox Laboratories, Vancouver, B. C., Canada) at 2 U/ml was added to the cultures. The final cell concentration was 5 X 103/ml and 0.5-ml duplicates were plated in flat-bottomed Cell lines. HUVE cells were grown in culture as previously described (Faller, D. V., D. Ginsburg, T. Collins, J. Pober, and R. Tantravahi, manuscript submitted for publication) on gelatin-coated plates in the presence ofheparin and endothelial cell growth factor supplement (Sigma Chemical Co.) in M199 medium (Gibco, Grand Island, NY) with 20% FCS. Cells at passage 4-10 were used in these studies. HUVE at confluence in six-well tissue culture plates (9.6 cm2, Nunc, USA/Scientific Plastics, Ocala, FL) were incubated in 4 ml of HUVE growth medium/well-containing purified human IL-I (p 17; Genzyme Corp., Boston, MA), recombinant human IL-I beta (p 17; Genzyme Corp.), recombinant human IL-2 (Biogen, Cambridge, MA), recombinant human interferon gamma (y IFN; Genentech Inc., San Francisco, CA), or recombinant human TNF(Genentech Inc.) at the concentrations described in the text. Medium was harvested after 48 h, filtered, and stored at -20'C. The human endothelial cell line immortalized by the Kirsten sarcoma virus (HEC KSV) (Faller, D. V., et al., and reference 23), and immortalized human synovial cells (23) were also plated in six-well tissue culture plates at the same density as HUVE, and the medium was harvested after 48 h for BPA/CSA and GM CSF assay. Cell line HEC KSV was grown in the same M199 medium as the HUVE. The synovial cells were grown in Dulbecco's modified Eagle's medium with 10% FCS (Gibco).
Cytoplasmic RNA analysis for GM CSF. RNA was extracted from 106 HEC KSV, primary human foreskin fibroblasts, or HUVE (with or without a 48-h exposure to recombinant human IL-1 at a concentration of 10 U/ml) as previously described (24) . Serial dilutions of the RNA preparations were spotted onto nitrocellulose filters and hybridized to a 32P-labeled cDNA probe complementary to human GM CSF (25) . Labeling ofthe probe, hybridization conditions, and wash conditions were as described. Autoradiography was carried out at -70'C using enhancing screens (Dupont Co., Wilmington, DE). The intensity of the spots was determined by a densitometric scanner (Helena Laboratories, Beaumont, TX).
Results
We previously reported that enriched bone marrow progenitor cells, depleted of known accessory "helper" cell populations, were totally dependent on exogenous BPAs and CSAs for BFU E and CFU GM proliferation in vitro (17) . In the series of experiments reported below, 0.5-3.1% of the final enriched cell fraction formed BFU E and 1.0-2.3% formed CFU GM-derived colonies, with progenitor recovery ranging from 19 to 94%.
Immortalized human endothelial cellsproduce BSA and CSA. Conditioned medium (CM) from an HEC KSV was tested on enriched bone marrow progenitors in a sensitive BPA/CSA assay. Fig. 1 shows that the medium contained BPA and CSA (Fig. 1 A and B, respectively). Data from three experiments are normalized with the colony number induced by 5% Mo-CM taken as 100%. The HEC KSV-conditioned medium was at least as active as Mo-CM, which induced 620-1260 BFU E and 1660-2200 CFU GM-derived colonies. In two experiments, CM from human synovial cells immortalized by the same virus (HSC KSV) were negative in the assay for both BPA and CSA, as was growth factor medium alone. It was possible that synovial cell CM contained an inhibitor that masked a stimulatory effect. Our observation that IL-l induces both HSC KSV and fibroblasts from other sources to release BPA/CSA makes this very unlikely (manuscript in preparation) and therefore we did not carry out further mixing studies to exclude the presence of an inhibitor.
IL-I and TNF markedly enhance BPA/CSA production by primary human endothelial cells. CM derived from HUVE cultured in medium alone showed low but detectable levels ofBPA and CSA (Fig. 2, A and B, respectively) . CM (5%) from HUVE incubated in purified human IL-i (10 U/ml) or recombinant TNF (1,000 U/ml) markedly increased both BFU E-and CFU GM-derived colony number, in contrast to CM from HUVE incubated with the lymphokines IL-2 or y IFN, which had no effect on CSA/BPA production. When enriched bone marrow progenitors were incubated in endothelial growth medium alone or medium supplemented with IL-I, TNF, IL-2, or y IFN, no CSA/BPA was observed. To investigate the IL-l/TNF effect more fully, enriched bone marrow progenitors from three different aspirates were cultured with different concentrations of medium conditioned by unstimulated HUVE or HUVE incubated in either purified human IL-l (10 U/ml) or recombinant TNF (1,000 U/ml). It is evident from Fig. 3 that BFU E and CFU GM showed a detectable response to unstimulated HUVE CM. BFU E (Fig. 3 A) showed a marked response to CM from both IL-1-and TNF-treated HUVE, which did not plateau at 10% show a marked response to both Conditioned Medium (%) IL-1-and TNF-treated HUVE.
CFU GM show a greater response to IL-l-than to TNF-treated HUVE. Medium alone, medium and IL-l (IO U/ml), medium and TNF (1,000 U/ml), and HUVE uninduced medium + IL-I (10 U/ml) stimulated the formation of very few colonies (6, 5, 10 , and 8%, respectively at 10% CM). No dose-response relationship was observed with these controls and the colony numbers were never above background (data not shown).
CM, the highest concentration possible in our culture system. CFU GM showed a greater response to IL-I -treated HUVE than TNF-treated HUVE (Fig. 3 B) . Endothelial cells produce GM CSF. To identify the hematopoietic growth factor being produced by immortalized and early passage human endothelial cells, we assayed for the presence of an mRNA species homologous to human T lymphoblast cell line-derived GM CSF. Serial dilutions of RNA extracted from HEC KSV cells, early passage human dermal fibroblasts, and IL-I-induced or uninduced HUVE cells were dotted onto nitrocellulose filters and hybridized to GM CSF cDNA probe. IL-l and TNF are structurally dissimilar (26) and act on responsive target cells through distinct cell surface receptors (27) . However, they both induce a similar spectrum of protein synthesis changes that is characteristic of the reaction to inflammation or tissue injury, the acute phase response (28) . Our data broaden the range of proteins known to be induced by these two molecules. Whether GM CSF is an important acute phase protein in vivo is unknown, but it is interesting to speculate that production of GM CSF by endothelial cells at the site of inflammation through IL-I release by monocyte/macrophages could contribute to neutrophilia (29) , localization of neutrophils by migration inhibition (30) , and subsequent neutrophil activation (31) . IL-I-mediated GM CSA release may contribute to the leukocytosis of juvenile chronic myeloid leukemia (32).
The precise role of monocyte/macrophages in hematopoiesis is still uncertain. Monocytes (7) (8) (9) (10) and T-lymphocytes (33, 34) have been previously reported as major circulating cell sources of BPA and CSA, whereas fixed "stromal" endothelial cells (4-6, 12, 13) 
